AIM: To evaluate the influence of 11C-choline PET/CT on radiotherapy planning in prostate cancer patients.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
BACKGROUND: Precise information on the extension of prostate cancer is crucial for the choice of an appropriate therapeutic strategy. 11C-choline positron emission tomography (11C-choline PET/CT) has two roles in radiation oncology (RT): (1) patient selection for treatment and (2) target volume selection and delineation. In conjunction with high-accuracy techniques, it might offer an opportunity of dose escalation and better tumour control while sparing healthy tissues.
MATERIALS AND METHODS: We carried out a retrospective study in order to analyse RT planning modification based on 11C-choline PET/CT in 16 prostate cancer patients. Patients were treated with hypofractionated step-and-shoot Intensity Modulated Radiotherapy (IMRT), or Volumetric Modulated Arc Therapy (VMAT), and a daily cone-beam CT for Image Guided Radiation Therapy (IGRT). All patients underwent a 11C-choline-PET/CT scan prior to radiotherapy.
RESULTS: In 37.5% of cases, a re-delineation and new dose prescription occurred. Data show good preliminary clinical results in terms of biochemical control and toxicity. No gastrointestinal (GI)/genitourinary (GU) grade III toxicities were observed after a median follow-up of 9.5 months.
CONCLUSIONS: In our experience, concerning the treatment of prostate cancer (PCa), 11C-choline PET/CT may be helpful in radiotherapy planning, either for dose escalation or exclusion of selected sites.
López E, Lazo A, Gutiérrez A, Arregui G, Núñez I, Sacchetti A. Are you the author?
Radiotherapy and Oncology Department, ONCOSUR, Granada, Spain; Nuclear Medicine Department, CIMES-FGUMA, Málaga, Spain; Medical Physics Department, ONCOSUR, Granada, Spain; Radiology and Physical Medicine Department, Granada University, Spain.
Reference: Rep Pract Oncol Radiother. 2014 Dec 16;20(2):104-12.